October 28, 2016

news_art1

A federal appeals court has revived a proposed shareholder class action against Arena Pharmaceuticals Inc. and certain of its former executives and directors that alleges defendant concealed safety concerns about Arena’s weight loss drug, lorcsaserin.  Kaplan Fox filed the initial complaint in September 2010 and has served as lead counsel for the lead plaintiff and proposed class since August 2011.

May 19, 2016

New York, New York - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) announces a $12.5 million settlement subject to court approval between Air India Ltd. ("Air India") and a plaintiff class in In re: Air Cargo Shipping Services Antitrust Litigation, 06-MD-1775 (JG) (VVP), a multi-district litigation pending in the Eastern District of New York.

September 28, 2012

Kaplan Fox & Kilsheimer LLP announces a $2.43 billion settlement of a class action lawsuit against Bank of America Corporation and Merrill Lynch & Company and certain current and former officers and directors for violations of federal securities laws in connection with Bank of America’s acquisition of Merrill Lynch...

June 20, 2016

Robert Kaplan, Senior Partner at Kaplan Fox & Kilsheimer LLP, organized and moderated a panel entitled “New Developments in Private Merger Litigation” at the American Antitrust Institute 17th Annual Conference, “Living With Market Concentration? New Perspectives on Merger Policy” on June 16 at the National Press Club in Washington, DC.

May 8, 2016

New York, New York - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) announces a $35 million settlement subject to court approval between Air New Zealand Limited (“Air New Zealand”) and a plaintiff class in In re: Air Cargo Shipping Services Antitrust Litigation, 06-MD-1775 (JG) (VVP), a multi-district litigation pending in the Eastern District of New York.